Pilocarpine, Brimonidine, Oxymetazoline (PBO) Compound to Control Presbyopia Symptoms

Last updated: August 14, 2021
Sponsor: Optall Vision
Overall Status: Active - Recruiting

Phase

1

Condition

Presbyopia

Treatment

N/A

Clinical Study ID

NCT05006911
PBOPC02
  • Ages 40-60
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Safety and Efficacy of Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic acid, Bromfenac (PBOHB) ophthalmic compound to improve uncorrected near vision in healthy presbyopic patients one hour after instillation.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Healthy
  • Presbyopic
  • 40 - 60 years

Exclusion

Exclusion Criteria:

  • Diabetics
  • Previous eye surgery
  • Previous eye disease
  • > 0.50 myopia
  • > 1.5 hyperopia or astigmatism

Study Design

Total Participants: 11
Study Start date:
August 14, 2021
Estimated Completion Date:
September 15, 2021

Study Description

To determine the safety and efficacy of a novel pharmacological compound of Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic acid, Bromfenac (PBOHB) to improve uncorrected near vision in healthy presbyopic patients one hour after binocular instillation.

Connect with a study center

  • Optall Vision

    Mexico City, 01090
    Mexico

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.